New chondrocyte patents for SpinalCyte
| Spinal News International

SpinalCyte recently announced the issuance of new patents in the USA and Japan. The company’s patent portfolio now includes 39 US and international patents issued with over 100 patents pending focused on the clinical use of fibroblasts. The company received investigational new drug clearance from the US Food and Drug Administration in November 2018 to […]

SpinalCyte receives new regenerative medicine patents: 5 insights
| Becker's Spine Review

SpinalCyte was issued new patents in the U.S. and Japan. Five things to know: 1. SpinalCyte is a regenerative medicine company focused on spinal disc regrowth using human dermal fibroblasts. 2. The company’s CybroCell product is the first off-the-shelf allogenic human dermal fibroblast product. It’s used indegenerative disc disease treatments. 3. The patents describe methods to differentiate […]

Regenerative Medicine Companies Successfully Advance Stem Cell Therapies
| Pharmaceutical Executive

Stem cell therapy development is a new area where several companies are emerging with promising results utilizing stem cell therapies. Some companies have failed, whereas others, such as Athersys, are succeeding. Gil Van Bokkelen, PhD, CEO of Athersys, will discuss his perspective on the recent advancements in stem cell therapies and their multiple application on […]